Gender, Histology, and Time of Diagnosis Are Important Factors for Prognosis: Analysis of 1499 Never-Smokers with Advanced Non-small Cell Lung Cancer in Japan-Reference-Cited by-同舟云学术

Gender, Histology, and Time of Diagnosis Are Important Factors for Prognosis: Analysis of 1499 Never-Smokers with Advanced Non-small Cell Lung Cancer in Japan

Published:2010-07 Issue:7 Volume:5 Page:1011-1017
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Kawaguchi Tomoya,Takada Minoru,Kubo Akihito,Matsumura Akihide,Fukai Shimao,Tamura Atsuhisa,Saito Ryusei,Kawahara Masaaki,Maruyama Yosihito

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference24 articles.

1. Lung cancer in never smokers—a different disease;Sun;Nat Rev Cancer,2007

2. Molecular genetics of lung cancer in people who have never smoked;Subramanian;Lancet Oncol,2008

3. Global cancer statistics, 2002;Parkin;CA Cancer J Clin,2005

4. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected];Fukuoka;J Clin Oncol,2003

5. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial;Kris;JAMA,2003

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long‐term outcome of definitive radiotherapy for locally advanced non‐small cell lung cancer: A real‐world single‐center study in the pre‐durvalumab era;Cancer Medicine;2024-07-31

2. Prognostic factors and predictive model construction in patients with non-small cell lung cancer: a retrospective study;Frontiers in Oncology;2024-05-24

3. A novel microRNA miR-4433a-3p as a potential diagnostic biomarker for lung adenocarcinoma;Heliyon;2024-05

4. Evaluation of Risk Factors for Lung Cancer Among Never Smokers and Their Association With Common Driver Mutations;Cureus;2024-03-12

5. Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations;JTO Clinical and Research Reports;2024-02